Antifungal Activity of Chitosan-Coated Poly(lactic-co-glycolic) Acid Nanoparticles Containing Amphotericin B

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Mycopathologia

• Publication date

  2018-03-01

• Fields of study

  Biology, Medicine, Materials Science

• Identifiers
  DOI 10.1007/s11046-018-0253-xPMID 29497926
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Xanthomonas citri MinC Oscillates from Pole to Pole to Ensure Proper Cell Division and Shape

  2017cited by this paper
• Assessment of in vitro antifungal efficacy and in vivo toxicity of Amphotericin B-loaded PLGA and PLGA-PEG blend nanoparticles.

  2017cited by this paper
• Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision

  2017cited by this paper
• Nanoparticles as safe and effective delivery systems of antifungal agents: Achievements and challenges.

  2017cited by this paper
• Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis

  2017cited by this paper
• The antifungal effect of silver nanoparticles on Trichosporon asahii.

  2016cited by this paper
• Role of nanoparticle size, shape and surface chemistry in oral drug delivery.

  2016cited by this paper
• PLGA-based nanoparticles: A new paradigm in biomedical applications

  2016cited by this paper
• Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

  2016cited by this paper
• Formación médica continuada: Infección fúngica invasora Candidemia y candidiasis invasora en el adulto. Formas clínicas y tratamiento

  2016cited by this paper
• Amphotericin B-loaded polymeric nanoparticles: formulation optimization by factorial design

  2016cited by this paper
• Dual chitosan/albumin-coated alginate/dextran sulfate nanoparticles for enhanced oral delivery of insulin.

  2016cited by this paper
• Reviewing the importance and evolution of fungal infections and potential antifungal resistance in haematological patients.

  2015cited by this paper
• Bovine Serum Albumin Nanoparticles Containing Amphotericin B: Characterization, Cytotoxicity and In Vitro Antifungal Evaluation.

  2015cited by this paper
• Poly(L-lactide) Nanoparticles Reduce Amphotericin B Cytotoxicity and Maintain Its In Vitro Antifungal Activity.

  2015cited by this paper
• Cellular uptake, antioxidant and antiproliferative activity of entrapped α-tocopherol and γ-tocotrienol in poly (lactic-co-glycolic) acid (PLGA) and chitosan covered PLGA nanoparticles (PLGA-Chi).

  2015cited by this paper
• Activity and in vivo tracking of Amphotericin B loaded PLGA nanoparticles.

  2015cited by this paper
• Biodistribution of PLGA and PLGA/chitosan nanoparticles after repeat-dose oral delivery in F344 rats for 7 days.

  2014cited by this paper
• Preparation and characterization of amorphous amphotericin B nanoparticles for oral administration through liquid antisolvent precipitation.

  2014cited by this paper
• Corrigendum to "Antimicrobial effects of silver nanoparticles" (Nanomed Nanotechnol Biol Med. 2007;1:95-101)

  2014cited by this paper
• Distribution of Candida species isolated from blood cultures in hospitals in Osaka, Japan.

  2014cited by this paper
• Stealth Amphotericin B nanoparticles for oral drug delivery: In vitro optimization

  2014cited by this paper
• Clinical practice guidelines for the management of invasive Candida infections in adults in the Middle East region: Expert panel recommendations.

  2014cited by this paper
• Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations.

  2013cited by this paper
• Pharmaceutical nanotechnology for oral delivery of anticancer drugs.

  2013cited by this paper
• Antifungal Activity of Nanocapsule Suspensions Containing Tea Tree Oil on the Growth of Trichophyton rubrum

  2013cited by this paper
• Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity

  2013cited by this paper
• Invasive fungal infections in patients with cancer in the Intensive Care Unit.

  2012cited by this paper
• Brazilian guidelines for the management of candidiasis – a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical

  2012cited by this paper
• PLGA nanoparticles and nanosuspensions with amphotericin B: Potent in vitro and in vivo alternatives to Fungizone and AmBisome.

  2012cited by this paper
• ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases.

  2012cited by this paper
• [Candidemia and invasive candidiasis in the adult: clinical forms and treatment].

  2012cited by this paper
• Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.

  2012cited by this paper
• The Yeasts, a Taxonomic Study, 5th ed

  2011cited by this paper
• The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems--a review.

  2011cited by this paper
• Emerging opportunistic yeast infections.

  2011cited by this paper
• Nanomedicine, Nanotechnology in medicine

  2011cited by this paper
• [The Spanish Society of Paediatric Infectious Diseases (SEIP) recommendations on the diagnosis and management of invasive candidiasis].

  2011cited by this paper
• [Guidelines for the treatment of Invasive Candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 Update].

  2011cited by this paper
• Candida albicans biofilms formed into catheters and probes and their resistance to amphotericin B.

  2011cited by this paper
• Pharmaceutical nanotechnology: Unmet needs in drug delivery.

  2010cited by this paper
• Nanosomal Amphotericin B is an efficacious alternative to Ambisome for fungal therapy.

  2010cited by this paper
• Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

  2009cited by this paper
• Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles.

  2008cited by this paper
• Amphotericin B formulations and drug targeting.

  2008cited by this paper
• Present situation in the treatment of invasive fungal infection.

  2008cited by this paper
• Antimicrobial effects of silver nanoparticles.

  2007cited by this paper
• Néphrotoxicité de l'amphotéricine B : mise au point

  2006cited by this paper
• Interactions of the drug amphotericin B with phospholipid membranes containing or not ergosterol: new insight into the role of ergosterol.

  2002cited by this paper
• Amphotericin biosynthesis in Streptomyces nodosus: deductions from analysis of polyketide synthase and late genes.

  2001cited by this paper
• Contributions to a revision of the genus Trichosporon.

  1992cited by this paper
• Polyene macrolide antibiotic amphotericin B. Crystal structure of the N-iodoacetyl derivative.

  1971cited by this paper

• Unleashing the translational potential of seriniquinone by PLGA nanoparticles: improved solubility, enhanced antimelanoma activity, and first in vivo administration in Galleria mellonella

  2026cites this paper
• Hybrid Soluplus–lipid nanoparticles for amphotericin B delivery: Formulation optimization, solid-state characterization, and in vitro antifungal activity

  2026cites this paper
• Synthesis and characterization of two novel amphotericin B-chitosan nanoparticles crosslinked with glutaraldehyde and Phthaldialdehyde for the treatment of invasive candidiasis.

  2025cites this paper
• Bloodstream infection in a neonatal intensive care unit: Epidemiology, Antifungal susceptibility and new drug delivered strategies.

  2025cites this paper
• Mild Oxidation of Plant Polyphenols Yields Modular Nanoparticle‐Forming Materials with Drug Loading Capabilities

  2025cites this paper
• Fusarium Head Blight management with nanotechnology: Advances and future prospects

  2025cites this paper
• Trimethyl Chitosan-Based Amphotericin B Nanoparticles: Improved Gastrointestinal Stability, Hemocompatibility, Monomeric Stabilization, and Controlled Drug Release

  2025cites this paper
• Chitosan-Coated PLGA Nanospheres for Improved Amphotericin B Delivery: Characterization, Mucoadhesion, and Cytotoxicity Assessment

  2024cites this paper
• Targeted delivery of amphotericin B-loaded PLGA micelles displaying lipopeptides to drug-resistant Candida-infected skin.

  2024cites this paper
• Amphotericin B: Insight into the advances in preclinical and clinical development

  2024cites this paper
• Fungal vaccines and adjuvants: a tool to reveal the interaction between host and fungi

  2024cites this paper
• Advances in nanotechnology for improving the targeted delivery and activity of amphotericin B (2011–2023): a systematic review

  2024cites this paper
• Fluconazole and propolis co-encapsulated in chitosan nanoparticles for the treatment of vulvovaginal candidiasis in a murine model.

  2023cites this paper
• The Antibiofilm Role of Biotics Family in Vaginal Fungal Infections

  2022cites this paper
• Review of Novel Oral Amphotericin B Formulations for the Treatment of Parasitic Infections

  2022cites this paper
• Amphotericin B-Loaded Plant-Inspired Polyphenol Nanoparticles Enhance Its Antifungal Activity and Biocompatibility.

  2022cites this paper
• Preparation and evaluation of red propolis and nystatin cyclodextrin inclusion complexes against oral microbiome opportunistic microorganisms

  2022cites this paper
• Delivery strategies of amphotericin B for invasive fungal infections

  2021cites this paper
• Nanomaterials for the Diagnosis and Treatment of Urinary Tract Infections

  2021cites this paper
• Mycopathologia 2020: Legacy and Change to Remain Relevant for Content, Creation, and Communication

  2021cites this paper
• Antimicrobial Actions and Applications of Chitosan

  2021cites this paper
• Nanoparticles as Potential Novel Therapies for Urinary Tract Infections

  2021cites this paper
• Amphotericin B-loaded Eudragit RL100 nanoparticles coated with hyaluronic acid for the treatment of vulvovaginal candidiasis.

  2020cites this paper
• Antifungal Nanomaterials: Current Progress and Future Directions

  2020cites this paper
• Nanosystems against candidiasis: a review of studies performed over the last two decades

  2020cites this paper
• The use of nanoparticles as alternative therapeutic agents against Candida infections: an up-to-date overview and future perspectives

  2020cites this paper
• Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections

  2020cites this paper
• Study on the bacteriostatic action of Chinese herbal medicine on avian Trichosporon

  2020cites this paper
• Assembly and antifungal effect of a new fluconazole-carrier nanosystem.

  2020cites this paper
• Nanoparticles as A Tool for Broadening Antifungal Activities.

  2020cites this paper
• Antifungal susceptibility of Candida species to copper oxide nanoparticles on polycaprolactone fibers (PCL-CuONPs)

  2020cites this paper
• Biofilms and vulvovaginal candidiasis.

  2019cites this paper
• Oriented Assembly of Cell-Mimicking Nanoparticles via a Molecular Affinity Strategy for Targeted Drug Delivery.

  2019cites this paper
• Recent Trends in Antifungal Agents: A Reference to Formulation, Characterization and Applications

  2019cites this paper
• Mucoadhesive chitosan-coated PLGA nanoparticles for oral delivery of ferulic acid

  2018cites this paper